OVID News and Press, Ovid Therapeutics Inc. From 12/01/23

Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide further evidence characterizing OV350 and its anticipated seizure reduction and neuroprotectiv...

Ovid Therapeutics Inc. (OVID) is expected to report $-0.18 for Q3 2023

2023-11-03 16:18:41 ET Ovid Therapeutics ( OVID ) on Friday filed a prospectus for a mixed securities shelf offering of up to $250M. This prospectus is not an offer to sell these securities. SEC Filing For further details see: Ovid Therapeutics files for $25...

2023-11-03 10:19:14 ET More on Ovid Therapeutics Ovid Therapeutics: The GABA Gambit In Seizure Wars Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid Therapeutics for $30M Seeking Alpha’s Quant Rating on Ovid Therapeutics Historica...

Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash runway into 2026 Clinical trials studying soticlestat as a treatment for Lennox-Ga...

2023-10-18 11:05:36 ET More on Ligand Pharmaceuticals, Ovid Therapeutics, etc. Ovid Therapeutics: The GABA Gambit In Seizure Wars Ligand: Nothing Exciting Stands Out For further details see: Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid T...

Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid Ovid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway into 2026 while simultaneously retaining 87% of the interest in soticlestat Trans...

2023-10-12 17:48:17 ET Gainers: Comtech Telecommunications  ( CMTL ) +14% . Relay Therapeutics ( RLAY ) +12% . Ovid Therapeutics  ( OVID ) +6% . Groupon ( GRPN ) +5% . Omeros Corporation ( OMER ) +4% . Losers: O...

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a presentation at ...

2023-10-04 07:14:23 ET Summary Ovid Therapeutics' OV329 shows promise in early Phase 1 data for treating pharmacoresistant epilepsy, boasting superior pharmacokinetics and safety profiles. Financials are strong with a robust current ratio of 10.1 and 24-month cash runway, but cash...